Lpl Financial LLC Cardiff Oncology, Inc. Transaction History

Lpl Financial LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $924 - $1,926	-600 Reduced 2.27%	25,784 $40,000
Q2 2022 Aug 12, 2022	BUY	$1.17 - $2.61 $4,677 - $10,434	3,998 Added 17.86%	26,384 $58,000
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $626 - $2,153	-297 Reduced 1.31%	22,386 $56,000
Q4 2021 Feb 14, 2022	BUY	$5.18 - $7.24 $26,329 - $36,800	5,083 Added 28.88%	22,683 $136,000
Q2 2021 Aug 13, 2021	BUY	$6.65 - $10.04 $9,975 - $15,059	1,500 Added 9.32%	17,600 $117,000
Q1 2021 May 14, 2021	BUY	$9.1 - $19.57 $1,237 - $2,661	136 Added 0.85%	16,100 $149,000
Q4 2020 Feb 12, 2021	BUY	$12.02 - $24.71 $21,804 - $44,823	1,814 Added 12.82%	15,964 $287,000
Q3 2020 Nov 09, 2020	BUY	$4.25 - $14.19 $60,137 - $200,788	14,150 New	14,150 $201,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.